ACACA and metabolic dysfunction-associated steatotic liver disease: Previous studies have revealed that ACC1 was highly expressed in NAFLD/NASH, while pharmacological inhibition of ACC1 offers a therapeutic approach for hepatic steatosis by inhibiting lipogenesis (Goedeke et al., 2018; Ross et al., 2020).